- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies | ||
| Fr | Verona completes enrolment in pilot study of potential COVID-19 inhaler | ||
| Fr | US breakthrough designation for ligelizumab in chronic spontaneous urticaria | ||
| Fr | NICE backs GSK's Zejlua in advanced ovarian cancer | ||
| Do | NHS England selects supermarket Asda to operate COVID-19 vaccination centre | ||
| Do | EU approval for ViiV's Tivicay for children living with HIV | ||
| Do | Valneva partners with Oxford Immunotec on T cell analysis for COVID-19 vaccine | ||
| Do | Gilead and Vir unite to find a 'functional cure' for hepatitis B | ||
| Mi | Roche's Tecentriq/Avastin combo improves survival in liver cancer | ||
| Mi | Diurnal seeks marketing authorisation for Chronocort in the UK | ||
| Mi | Eli Lilly announces mid-stage trial success for donanemab in Alzheimer's | ||
| Mi | Synairgen begins large-scale trial of inhaled COVID-19 treatment | ||
| Di | Biogen and Apple partner on cognitive health study | ||
| Di | ICR researchers identify potential new treatment for drug-resistant prostate cancer | ||
| Di | DHSC publishes 'UK Rare Disease Framework' | ||
| Di | UK government unveils 'largest vaccination programme in British history' | ||
| Mo | Boehringer Ingelheim announces partnership with Google | ||
| Mo | EU OK for Roche's oral flu treatment Xofluza | ||
| Mo | Sanofi to acquire Kymab for up to $1.45bn | ||
| Mo | England to launch rapid asymptomatic COVID-19 testing this week | ||
| 08.01. | BREAKING NEWS: Moderna's COVID-19 vaccine granted authorisation in UK | ||
| 08.01. | NHS Digital pilot will collect private hospital data | ||
| 08.01. | MHRA review recommends discussion around epilepsy medication and pregnancy | ||
| 08.01. | Tocilizumab and sarilumab cut risk of death in severe COVID-19 patients | ||
| 08.01. | NICE no for BMS' Opdivo for head and neck cancer |
sist1
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
